Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

232.16

-0.61 (0.26%)

as of Jun 8, 2026, 8:00:00 pm Market Open.

698 watching

Investor Insights

Jun 8, 2026, 12:00 am

This summary was created by AI, based on 12 opinions in the last 12 months.

Johnson & Johnson (JNJ) has been experiencing a transformative period, especially following the spinoff of its orthopedics division, allowing it to focus more on pharmaceuticals and medical devices. Experts have highlighted the company's strong drug pipeline and robust performance in its core pharmaceutical business, which has led to a significant increase in stock value this year. Despite some concerns regarding ongoing talcum powder litigation and its past underwhelming performance, many analysts believe the legal risks are diminishing. The stock is seen as a better long-term hold, with potential dividend growth, especially amidst a broader economic context affecting consumer products. Overall, JNJ is viewed as an attractive investment, particularly when bought on weakness, with the valuation appearing favorable due to its premium position in the healthcare sector.

Consensus

Buy

Valuation

Fair Value

Similar

BUY

JNJ vs. PG Valuation of 16-17x earnings is cheaper than PG. A healthcare company: medical devices, healthcare, pharma. PG is just consumer products, trading at 23x earnings. More opportunity in JNJ, with a caveat on the talc lawsuits. Medical device side should do well post-Covid. Dividends similar in the 2.5% range.

BUY ON WEAKNESS

It has been a great long term stock. He would own it if it were a little cheaper. They are in a good sector. The entry point is too expensive, otherwise he would like to own it.

BUY

Doesn't own, but likes it. Steady, strong technical chart on the upswing. 17x earnings for a 9% growth rate. Diversified products, strong management. Great for cashflow and long-term growth. He prefers Pfizer and ABBV. See his Top Picks today. Yield is 2.6%.

BUY

Great company because of its diversified businesses of pharma, medical devices, and personal care products. Great dividend yield, increased for 54 years in a row. Great free cashflow growth.

BUY

It is a stable holding, which has in fact been a headwind. It will probably ebb and flow. There are some company specific catalysts there as well, though.

BUY

It's a teflon stock with a good drug pipeline. This will go up no matter what.

HOLD

JNJ vs. ABT Healthcare is in a more defensive space, moving up during the pandemic. Likes both. JNJ has a fairly nice dividend at 2.5%. 18x forward earnings for 8% growth. Performing decently, but underperforming the S&P. ABT is more in medical devices. Marginally underperforming since last March. 22x earnings with a higher growth rate of 14%. Bit more torque with ABT, and they're also in the Covid detection space. If he had to choose, it would be ABT.

BUY

Opportunity for Pfizer and J&J are solid. You give up some appreciation when you select a stock with higher yield. However, total return is the most important. There is more diversification with JNJ with medical supplies. Pfizer's partnership with BioNtech is positive. There is renewed chatter about drug price controls. Both offer good prospective.

PAST TOP PICK

(A Top Pick May 11/20, Up 16%) Great dividend yield, and keeps increasing. Trades at 18x earnings. Likes its 3 divisions of pharma, medical devices, and personal care. This smooths out the volatility and revenue. Cashflow machine.

BUY

They report Tuesday. The CDC, he feels, has unfairly punished JNJ over its Covid vaccine. He expects JNJ to release a strong quarter and pipeline of drugs.

DON'T BUY

This morning the news said that distribution has been halted in the US, so the stock is declining today. Like Pfzier, JNJ is seeing a one-time bump because of their vaccine. JNJ is struggling in their consumer business as consumers move to generic drugs, not branded. Also, litigation remains a cloud, referring to asbestos in its Baby Powder. There are other opportunities in healthcare, like Anthem, the insurer, or retailer CVS, or Abbvie trading at a reasonable PE and offers good growth.

PAST TOP PICK

(A Top Pick Mar 12/20, Up 34%) A great company. Pharma, medical technology and consumer products are its three divisions, so if one lags, the others pick up the slack. Has great cash flow and pays an increasing yield. They came out with a Covid vaccine quickly. Developing drugs is a risk, because it depends on FDA approval, but JNJ operates three divisions to spread overall risk. He likes that, unlike pure pharma which depend on their drug pipeline.

WATCH

Has many brands that are billion dollar platforms. Consistent growth over last 25 years. High quality. Good positioning in consumer healthcare, pharma, and medical devices. On his focus list.

TOP PICK

It's done relatively year. Their pharma pipeline remains strong and accounts for nearly half their revenues. The medical devices business is a recovery play as elective surgeries will see a ramp up after delays from Covid. JNJ will grow earnings in double-digits for the next couple years. It trades at a reasonable 17x PE. Has a strong balance sheet, and has raised its dividend for 58 straight years (now 2.5%). She likes healthcare long term. JNJ won't make much money off their vaccine, but their pharma pipeline is solid. (Analysts’ price target is $183.68)

BUY

They boast a long track record of paying dividends. They produced an approved one-shot Covid vaccine. JNJ has a good history of doing right for its shareholders. Great balance sheet and has a history of developing new job. JNJ won't make a lot of money off its Covid vaccine. It has the best balance sheet of any large company in the U.S.

Showing 136 to 150 of 626 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)